The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Serotonin receptors : their key role in drugs to treat schizophrenia
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A review of central 5-HT receptors and their function
Barnes, N. M., & Sharp, T. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00010-6 · Cited by 3,161
Sokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L., & Schwartz, J.-C. (1990) · Nature · doi:10.1038/347146a0 · Cited by 2,609
Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia
Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D., & Weinberger, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111134598 · Cited by 2,381
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,148
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Modulation of memory fields by dopamine Dl receptors in prefrontal cortex
Williams, G. V., & Goldman-Rakic, P. S. (1995) · Nature · doi:10.1038/376572a0 · Cited by 1,593
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Self-citationD1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory
Sawaguchi, T., & Goldman-Rakic, P. S. (1991) · Science · doi:10.1126/science.1825731 · Cited by 1,364
Cited by
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Bilder, R. M., Volavka, J., Lachman, H. M., & Grace, A. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300542 · Cited by 769
“…to increase medial prefrontal DA release, and these mechanisms have been proposed as possible routes for cognitive enhancing properties of multiple atypical antipsychotic agents including clozapine, risperidone, olanzapine, quetiapine, and ziprasidone (Ichikawa et al, 2001; Meltzer et al, 2003).”
BackgroundPharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission
Alex, K. D., & Pehek, E. A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.004 · Cited by 658
Current Concepts and Treatments of Schizophrenia
Stępnicki, P., Kondej, M., & Kaczor, A. A. (2018) · Molecules · doi:10.3390/molecules23082087 · Cited by 556
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Schizophrenia: overview and treatment options.
(2014) · PubMed Central · Cited by 533
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 517
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature
Shahid, M., Walker, G., Zorn, S., & Wong, E. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881107082944 · Cited by 493
Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia
Horacek, J., Bubenikova-Valesova, V., Kopecek, M., Palenicek, T., Dockery, C., Mohr, P., & H??schl, C. (2006) · CNS Drugs · doi:10.2165/00023210-200620050-00004 · Cited by 461
Ishibashi, T., Horisawa, T., Tokuda, K., Ishiyama, T., Ogasa, M., Tagashira, R., Matsumoto, K., Nishikawa, H., Ueda, Y., Toma, S., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167346 · Cited by 438
Thomsen, W. J., Grottick, A. J., Menzaghi, F., Reyes-Saldana, H., Espitia, S., Yuskin, D., Whelan, K., Martin, M., Morgan, M., Chen, W., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.133348 · Cited by 402
Kodama, M., Fujioka, T., & Duman, R. S. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.07.008 · Cited by 387
Kiss, B., Horváth, A., Némethy, Z., Schmidt, É., Laszlovszky, I., Bugovics, G., Fazekas, K., Hornok, K., Orosz, S., Gyertyán, I., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160432 · Cited by 367
Prefrontal Serotonin Depletion Affects Reversal Learning But Not Attentional Set Shifting
Clarke, H. F., Walker, S. C., Crofts, H. S., Dalley, J. W., Robbins, T. W., & Roberts, A. C. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3690-04.2005 · Cited by 358
“Specifically, dysregulation of prefrontal serotonin is hypothesized to contribute to the behavioral impairments associated with schizophrenia (Meltzer et al., 2003), depression (Meltzer, 1989), and obsessive-compulsive disorder (OCD) (Blier and de Montigny, 1998).”
BackgroundClarke, H., Walker, S., Dalley, J., Robbins, T., & Roberts, A. (2006) · Cerebral Cortex · doi:10.1093/cercor/bhj120 · Cited by 351
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
Arranz, M. J., & de Leon, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002009 · Cited by 351
Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review
Stone, J. M., Morrison, P. D., & Pilowsky, L. S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073126 · Cited by 348
van den Buuse, M. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp132 · Cited by 346
Juckel, G., Schlagenhauf, F., Koslowski, M., Filonov, D., Wüstenberg, T., Villringer, A., Knutson, B., Kienast, T., Gallinat, J., Wrase, J., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0405-4 · Cited by 323
Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions
MILLAN, M., MARIN, P., BOCKAERT, J., & MANNOURYLACOUR, C. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.06.007 · Cited by 320
Serotonergic modulation of the limbic system
Hensler, J. G. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.06.007 · Cited by 319
Jensen, N. H., Rodriguiz, R. M., Caron, M. G., Wetsel, W. C., Rothman, R. B., & Roth, B. L. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301646 · Cited by 316
Serotonin receptors involved in antidepressant effects
Artigas, F. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.006 · Cited by 311
Meltzer, H. Y., Mills, R., Revell, S., Williams, H., Johnson, A., Bahr, D., & Friedman, J. H. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.176 · Cited by 292
Self-citationMillan, M. J. (2005) · Therapies · doi:10.2515/therapie:2005065 · Cited by 283
Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine
Schlagenhauf, F., Juckel, G., Koslowski, M., Kahnt, T., Knutson, B., Dembler, T., Kienast, T., Gallinat, J., Wrase, J., & Heinz, A. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1016-4 · Cited by 204
Abi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179
Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective
Tse, L., Barr, A., Scarapicchia, V., & Vila-Rodriguez, F. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13999150424113345 · Cited by 179
Carrard, A., Salzmann, A., Malafosse, A., & Karege, F. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.03.018 · Cited by 138
The neural underpinnings of cognitive flexibility and their disruption in psychotic illness
Waltz, J. A. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2016.06.005 · Cited by 122
“Given that all effective antipsychotic drugs (APDs) occupy dopamine D2-type receptors (almost all being antagonists; Seeman, 1987, Seeman and Tallerico, 1998) and that many also occupy postsynaptic serotonin receptors (Meltzer et al., 2003), it is reasonable to think that APDs might modulate reinforcement learning and…”
BackgroundInfluentialCerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
SPORN, A. L., VERMANI, A., GREENSTEIN, D. K., BOBB, A. J., SPENCER, E. P., CLASEN, L. S., TOSSELL, J. W., STAYER, C. C., GOCHMAN, P. A., LENANE, M. C., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31812eed10 · Cited by 107
Mirjana, C., Baviera, M., Invernizzi, R. W., & Balducci, C. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300479 · Cited by 102
Brand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95
Wienberg, M., Glenthoj, B., Jensen, K., & Oranje, B. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109102606 · Cited by 68
Athilingam, J. C., Ben-Shalom, R., Keeshen, C. M., Sohal, V. S., & Bender, K. J. (2017) · eLife · doi:10.7554/elife.31991 · Cited by 49
“Selective serotonin reuptake inhibitors (SSRIs) remain the most commonly used treatments for depression (Risch and Nemeroff, 1992; Willner, 1985) and second-generation antipsychotics used in schizophrenia block the 5HT2A receptor with high affinity (Meltzer et al., 2003; Meltzer and Massey, 2011).”
Takano, H. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00228 · Cited by 34
Zhang, C., Tian, F., Peng, J., Wang, X., Li, J., Zhang, L., & Tan, Z. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14655 · Cited by 14
“25 These findings provide potential insights into the mechanism by which cy-proheptadine increases the concentration of 5-HT in the brain.”
Background
Metadata
- Authors
- Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J.
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 27
- Issue
- 7
- Pages
- 1159-1172
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2095213614
- Cited by
- 775
- References
- 167
- FWCI
- 25.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.